Astrazeneca refused close to £ 80m in state support for the canceled factory of the Speke

Unlock free Digest editor

Roula Khalaf, editor of FT, chooses her favorite story in this weekly newsletter.

Astrazeneca rejected the offer of almost £ 80m in state support in the UK when she abruptly canceled plans for a vaccine production in the amount of £ 450 million near Liverpool, according to the people who reported on the issue.

Pharmaceuticals Group, the most prized company in the UK list, rejected the Government’s offer on a tense meeting on Wednesday afternoon, just hours after Chancellor Rachel Reeves checked Astrazenec in speech as one of the British “big companies”, people said.

Astrazeneca also raised a series of unrelated questions with the Government during the negotiations of a planned vaccine plant in Merseyside, including the NHS rejection of breast cancer drugs and a health service price for health service, according to three persons who drawn the discussions.

A new context for the Astrazenec statement on Friday provides a report on the interviewing of the negotiations that: “Several factors have influenced this decision, including the time and reduction of the final offer compared to the proposal of the previous government.”

The Starmer Labor Government sought last summer after taking over her duty to reduce the amount of public money provided at the Speke at £ 40m factory, which is a drop of around £ 90m promised by the former conservative government.

The £ 90 million offer within Tori consisted of £ 70 million in grants for the Specke and £ 20m Factory in research and the development of the UK support of Health Security Agency.

This month, the UK officials presented a revised total offer of £ 78 million in financial support, according to people who are familiar with this issue.

The initial decrease in state support came after government officials made due attention at the level of investment in the research and development promised by the Astrazenec, according to several people who were familiar with the negotiations.

Officials have concluded that the company proposes less investments than it was initially expected and as a result, the Government reduced its proposed contribution, people said.

Astrazeneca refused to comment. The treasury said: “All state funds must show the value of the taxpayer, and the change in the investment proposed by the Astrazenec has led to set a reduced government offer.”

Astrazenec’s decision to cancel the £ 450 million plant, which was charged as the next generation of flu vaccine production for flu and potentially emergency diseases, was a blow to Starmer and Reeves, who in recent weeks have asked to emphasize the United Kingdom’s attraction for work.

Work before the general elections in July 2024, he highlighted his credentials for business, including a vow that he would not raise profit tax. Although Reeves kept that promise in its first budget, it also reached a company with £ 25 billion a year in increased contributions to national insurance.

Kate Bingham, a managing partner at St. Health Investors Entrepreneurial Company and a former head of the Coid-19 vaccine, said that the specta factory had canceled “continues the sad topic where the Hand Hands Bites.”

“The Life Science Sector is allegedly a major priority for growth in the UK, but the Government seems to lack the true expertise and a strategic way of thinking to achieve a productive partnership,” she said.

The Tories seized the dismissal, and the secretary of the shadow of Andrew Griffiths said: “There is no vaccine for incompetence.”

One person close to Astrazeneci said that the relationship between the pharmaceutical industry and the Government of the UK became quite “toxic”, adding that “we have one of the worst commercial environments for medicines in the Western world.”

The Astrazeneca is very investing in the United States, promising $ 3.5 billion late last year, as in other countries like Singapore and Canada.

Last year, the English Health Care Guardian refused to recommend the Astrazenec -O’s breast cancer drug for use by NHS, claiming that the price is too high. It was the first breast cancer remedy that was rejected by the National Institute of Health and Contemporary Excellence for more than six years.

Drug manufacturers including Astrazeneca Coffee tax unexpectedly rose This year, a reduction in the earnings of pharmaceutical groups could be made from the sale of new medicines to the British government.

The Executive CEO and the Industry Committee met last month from the Minister of Health Care WES Streeting to complain about having to pay 22.9 percent of their sales in the UK this year, which is much more than an intended 15 percent.

NHS England said that the purchase of potentially curative cellular and gene therapies, and medicines for conditions, including cancer, diabetes, eye diseases increased more than expected in 2024, which led to an increase in the tax rate.